With the current research focus on diagnosis of acute myocardial infarction (MI) by Positron Emission Tomography (PET), Hexakit, Inc. is a biopharmaceutical company engaged in diagnostic drug development for cardiovascular diseases. Myocardial Infarction (MI) is the leading cause of death in the US and in most developed nations throughout the world. The majority of heart failures are caused by myocardial ischemia secondary to coronary artery disease (CAD).
